Digest Network Come funziona
Network
/
Società
Co
Non verificato

Corcept Therapeutics Incorporated

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

33 comunicati stampa

Guarda tutti i comunicati
24/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
19/02/2026
Legge/Diritto
Scienza
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Salute
Farmaceutica
Sanità
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
17/02/2026
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Sanità
Oncologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
22/01/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
31/12/2026
Farmaceutica
Oncologia
Comunicazione
Sanità
Salute
Igiene alimentare
Industria
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
04/11/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Igiene alimentare
Biotecnologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Oncologia
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
28/10/2025
Sanità
Farmaceutica
Salute
Medicina - Varie
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
19/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
14/10/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
22/09/2025
Eventi
Fiere
Industria
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Oncologia
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0